The Trump administration has drawn a hard line on generic drug imports. A newly announced tariff plan gives foreign manufacturers a window, but the message is unmistakable: start moving production to the United States, or face duties high enough to make the economics collapse. Generic medicines will remain tariff-free until August 1, 2028. After that, the penalty rises in two sharp steps. A 100 percent tariff will hit imports from August 2028 through August 2029. Then, beginning in August 2029, the rate doubles to 200 percent. Companies that relocate manufacturing to American facilities can escape the charges entirely.

That timeline offers roughly three years of breathing room. In pharmaceutical terms, three years is both an eternity and a blink. Constructing a new FDA-compliant plant, validating processes, and securing supply lines can easily stretch across half a decade. Reconfiguring existing assets moves faster, which explains why the administration tucked in the exemption incentive. Firms that shift final manufacturing, packaging, or formulation work to the U.S. before the deadlines can keep selling without the tariff wall.

Whether that proves practical depends on where a company sits in the supply chain.

India's Central Role

India sits at the center of this storm. The country ships $9.7 billion worth of pharmaceuticals to the United States every year. Indian manufacturers already fill 47 percent of all generic prescriptions dispensed in America. Their competitive edge is brutal: many Indian generics sell for seven to ten times less than their branded equivalents.

That gap matters because generic drugs are not luxury goods. They are commoditized medications where a few cents per pill decide contract winners. When the starting price is a fraction of the alternative, even a hefty tariff might not zero out the advantage. Some analysts believe certain Indian products could absorb the 100 percent duty and still undercut competitors. Doubling the price of something that costs a dime does not automatically make it more expensive than a dollar alternative.

But the math changes at 200 percent. A duty that triples the landed cost of a product built on razor-thin margins would force either a dramatic price hike or a strategic retreat. Hospitals, pharmacies, and the government buyers who manage Medicare and Medicaid budgets would feel the ripple. American patients have grown accustomed to cheap generics precisely because Indian firms spent decades optimizing for scale. Disrupting that flow without a ready domestic replacement risks sticker shock at the pharmacy counter.

The API Problem

Here is where the policy runs into manufacturing reality. Generic drugmaking looks simple on the surface. You mix active pharmaceutical ingredients with binders, press tablets, bottle them, and ship. The complexity hides upstream. Those active ingredients, or APIs, are the real chokepoint.

Indian formulators import roughly 70 percent of their chemical-based APIs from China. For biologic inputs, the dependence is even steeper: about 90 percent comes from Chinese suppliers. This means a company could open a new plant in Indiana and still find itself tethered to raw materials crossing the Pacific.

Relocating pill production to the U.S. does not, by itself, solve that dependency. If Washington eventually extends similar tariff logic to API imports, the cost structure face-plants again. Building a fully vertical domestic supply chain, from petrochemical starting materials through intermediate synthesis to finished tablets, would require massive capital, a trained workforce, and environmental permits that take years to secure. No one in the industry believes that happens by August 2028. The tariff plan targets final formulation, but the supply chain runs deeper.

What the Companies Are Doing

Several Indian giants have already hedged their bets. Sun Pharma, Zydus Lifesciences, Lupin, Aurobindo Pharma, Cipla, and Dr. Reddy’s Laboratories all operate manufacturing plants inside the United States. These facilities are not new; they have served the American market for years, often handling specific dosage forms or institutional contracts rather than the full flood of retail generics.

そのバランスは変化している可能性がある。Ciplaはマサチューセッツ州とニューヨーク州で積極的に生産能力を拡大している。Dr. Reddy’s Laboratoriesは、米国での増産を検討していることを公に示唆している。これらの動きは、ゼロから作り直すことなく、少なくとも一定のボリュームを国境を越えて移管できることを示唆している。しかし、米国内に特化した施設を運営することと、現在アメリカ市場に供給している大量の製品を移管することの間には違いがある。米国の工場はインドでの生産を補完するものであり、それに取って代わるものではない。

米国の政策立案者は、リショアリングを国家の意志の問題として捉えることが多い。しかし、製薬業界は、それが化学と経済の問題であることを知っている。中国がAPI生産を支配しているのは、数十年前に反応器、廃棄物処理システム、およびサプライヤーネットワークを構築したからである。インドは、それらの中国産の原料を取り込み、可能な限り低いコストでFDAの基準を満たす錠剤へと変える、製剤における規制上の技術を習得することで、独自の地位を築き上げた。新しい関税スケジュールがこの分業体制を無視することは、自らを危険にさらすことになる。

患者と支払者への最終的な影響

患者と支払者にとって、短期的な見通しは不透明である。もしインドの輸出業者が100%の関税の一部でも価格に転嫁すれば、ジェネリック医薬品の価格は上昇する。もし市場シェアを維持するために関税を吸収すれば、利益率は圧縮され、品質や投資を削るという圧力が高まる。200%となれば、関税を正当化できるほどのアメリカでの価格上昇がない限り、ほとんどの企業は該当製品の出荷を単純に停止するだろう。いずれのシナリオにおいても、ジェネリック市場の決定的な特徴である、極限まで抑えられたコストが打撃を受ける。

免除条項は脱出口を提供しているが、それは米国内で再構築するための資本と忍耐力を持つ企業に限られる。米国での拠点を持たない小規模なジェネリックメーカーは淘汰される可能性があり、数百万ドル規模の施設アップグレードを賄える巨大企業へと権力が集中することになる。競争の減少は、それ自体が長期的なコストをもたらす。

この関税計画は、貿易調整というよりも、再編の最後...